This disclosure relates to a sterile solution product bag and, in particular, a sterile solution product bag having an integral filter that allows microbial and particulate matter filtration during filling in non-traditional settings.
Conventional methods for manufacturing bags of sterile solution include filling bags in a clean environment with a solution, sealing the filled bag of solution, and then sterilizing the fluid and bags in a sterilizing autoclave. This can be referred to as terminal sterilization. Another conventional method is to sterile filter a solution and to fill and seal sterile bags in an extremely high-quality environment designed and controlled to prevent contamination of the solution during the filling process and to seal the filled bag. This can be referred to as an aseptic filling process.
Terminal sterilization generally requires autoclaves to produce the sterilizing heat and steam needed. These autoclaves generally are not economical unless they can produce large batches of terminally sterilized bags. Thus the capital expenditure needed and space requirements lead to centralized manufacturing facilities that produce the filled bags and then ship them some distance to their destination for use. Also, the application of terminal sterilization processes may degrade the solution formulation thereby leading to incompatible or unstable formulations. Moreover, terminal sterilization does not eliminate non-viable contamination.
The aseptic manufacturing process must occur in a sterile working environments, and require expensive equipment, stringent procedures and extensive monitoring to ensure that solution product bags meet certain environmental and manufacturing regulatory standards. Sterilizing a working environment, by itself, can be costly and time consuming. Additional precautions apply for technicians involved in the filling process to ensure the production of safe and sterile products. Even with these safeguards, unless it can be verified that the solution entering the bag is sterile, there is a risk that contaminants may have inadvertently been introduced into the solution during filling/sealing, and once introduced, unless the solution later passes through a viable sterilizing filter, the contaminants will remain in the solution. Again due to these requirements, sterile solution product bags are often produced in centralized locations and shipped some distance to their destination for use.
Considering the costs associated with manufacturing sterile solution product bags, most health centers and clinics outsource their supply of sterile bags to manufacturing companies. To maintain the sterility of the shipment of bags, the sterile product bags must be carefully packaged and shipped to ensure safe delivery. As such, buying sterile product bags from a remote location may be very expensive and may increase the risk of contamination.
The current disclosure is directed to a sterile solution product bag having an integral sterilization grade filter such that the microbial and particulate matter filtration can be performed using the filter directly at the point of fill. The combination filter/container is pre-sterilized to SAL≤10−6 prior to filling. A benefit of the integration of the filter and the final container is that the filters can be sterilized after connection to the final container such that there is little to no risk of solution contamination after filtration. An additional benefit of this approach is that there is no requirement for a highly controlled and classified filling environment, thereby providing an opportunity for a very simplified filling environment that could be deployed in various non-traditional settings (e.g., pharmacies, patient homes, etc.). In some versions, the products bag(s) of the present disclosure can be filled with an automated or semi-automated filling machine/system such as those disclosed in U.S. Provisional Patent Application No. 62/281,825, entitled “METHOD AND MACHINE FOR PRODUCING STERILE SOLUTION PRODUCT BAGS,” filed on Jan. 22, 2016, the entire contents of which are expressly incorporated herein by reference. Additionally, the filter size can be reduced due to the limited volumes being processed for each filter, reducing the size and cost of each filter.
Embodiments within the scope of the present disclosure are directed to a product bag, the entire interior of which is pre-sterilized, and including a bladder, a stem, a filter, and a sterile closure cap. The bladder is a fillable pouch having a standard volume capacity with the pre-sterilized inner environment. The bladder is fluidly connected to the stem at an opening at a first end of the bladder. Administration and medicinal ports are disposed at a second end of the bladder.
In some embodiments within the scope of the present disclosure, the stem is a narrow tube that fluidly connects an inlet of the stem to the opening of the bladder. The stem may include a tapered head defining an inlet, a collar connecting a first stem part to the tapered head, a second part, and a duct defining a stem outlet. The sterile closure cap may have a hemispherical shaped knob attached to a neck of the stem that sealable covers the inlet of the stem.
In some embodiments within the scope of the present disclosure, the filter includes a flat sheet membrane filter or a hollow fiber membrane that is disposed in-line with the stem between the first and second parts of the stem. The tapered head of the stem may be a female fitting that sealing engages a Luer fitting. So configured, a solution may enter the inlet of the stem and sequentially pass through the head and into the first part toward an inlet of the filter. The solution then filters through the filter membrane, out a filter outlet, and into the second part of the stem. The duct fluidly connects the filtered solution from the second part and the opening of the bladder. The second part of the stem defined as the area of the stem between the outlet of the filter and an inlet of the duct may be identified as a cut and seal area. The stem provides an isolated fluid connection between the inlet and the bladder, such that once the solution is filtered through the membrane, the filtered solution passes directly into the sterilized environment of the bladder.
In other embodiments within the scope of the present disclosure, the stem, which may be tapered or cylindrical, does not provide separate inlet and outlet connection ports for the filter. Instead, the filter includes a hollow fiber filter membrane that conforms to the shape of the stem. In some embodiments within the scope of the present disclosure, a set of redundant filters in series in the stem may be used in conjunction with the product bag. In some embodiments within the scope of the present disclosure, one or more looped hollow fiber filter membranes may be secured within a filter body to allow quicker filtration. In other embodiments within the scope of the present disclosure, a plurality of hollow fiber filter membranes may be arranged side-by-side or in a circular pattern to form a bundled configuration that allows quicker filtration.
In some embodiments within the scope of the present disclosure, the product bags can be configured in such a way that a single filter can be used to process the solution of multiple product bags. For example, multiple product bladders may be arranged in a connected belt-like configuration connected to a single filter wherein filtered solution fills the bladders sequentially. Alternately, multiple bladders may be connected by sealable tubing to a single filter.
Each filter is a sterilization grade filter and includes a suitable sterilizing grade material having a plurality of pores, the filter having a nominal pore size in the range of from approximately 0.1 microns to approximately 0.5 microns, for instance, approximately 0.2 to approximately 0.4 microns. In some versions, each pore has a diameter that is less than or equal to approximately 0.2 microns. In some versions, each pore has a diameter that is less than or equal to approximately 0.22 microns. In some versions, the filter has a nominal pore size that is in a range of approximately 0.1 microns to approximately 0.2 microns. In some versions, the filter has a nominal pore size that is in a range of approximately 0.1 microns to approximately 0.22 microns. In characterizing the porosity of filter membranes, “nominal pore size” typically refers to the diameter of the smallest particle that cannot pass through the membrane. Porometry is commonly used to determine the nominal pore size. Most membrane filter producers characterize their filters by the First Bubble Point (FBP) as defined by ASTM F-316-03 (2011) “Standard Test Methods for Pore Size Characteristics of Membrane Filters by Bubble Point and Mean Flow Pore Test.” The nominal pore size is calculated from the FBP by using the Young-Laplace formula P=4*γ*cos θ*/D, in which D is the pore diameter, P is the pressure measured, γ is the surface tension of the wetting liquid and θ is the contact angle of the wetting liquid with the sample. In one test, a suitable flow rate for the measurement of FBP could be approximately 30 ml/min.
The filter so constructed effectively sterilizes and reduces the particulate matter level of the solution as it passes through the filter and into the bladder. Filling of the product bag may be performed at temperatures in excess of 60° C. for formulations that are compatible such that the residual microbial risks of viable organisms passing through the filter are further mitigated by pasteurization, or a similar heat treatment, in addition to filtration. Alternatively, hot filling may be replaced by a sterilization process immediately prior to filling, such as UV sterilization, thermal sterilization, electron beam sterilization, or the like.
In some embodiments, filter arrangements disclosed herein may be connected to a continuous ambulatory peritoneal dialysis (CAPD) twin bag container system. The CAPD twin bag container system allows delivery of essential peritoneal dialysis solutions to patients with end stage renal disease in locations in which treatment of such patients might not otherwise be possible. The twin bag container system includes a solution bag and a drain bag. An injection site may be provided on the solution bag for medication additives. Tubing runs from the solution bag and the drain bag to a patient connector. The patient connector interfaces with the transfer set of a patient's peritoneal dialysis (PD) catheter at the time of use. The patient connector may have a Y-junction at which the tubing connects. The tubing running from the solution bag to the patient connector may have a frangible portion just prior to the patient connector. The patient connector may have a sterility protector that may be removed immediately prior to use. In some embodiments, the filter arrangement may be connected at a filter Y-junction to the tubing running from the solution bag to the patient connector. In other embodiments, the filter arrangement may be connected to the solution bag by tubing entirely separate from the tubing running from the solution bag to the patient connector.
According to a first independent aspect, a sterile solution product bag is provided including a bladder, a stem and a filter. The stem has an inlet end and an outlet end, the outlet end of the stem fluidly connected to the bladder. The filter is disposed in line with the stem, the filter having a filter membrane with a nominal pore size in a range of approximately 0.1 μm to approximately 0.5 μm, wherein the filter membrane is shaped as a hollow fiber with pores residing in the wall of the fiber.
In a second aspect according to the previous aspect, the filter membrane is disposed inside of the stem between the inlet and outlet ends.
In a third aspect according to the previous aspects, the filter comprises a plurality of filter membranes.
In a fourth aspect according to the previous aspects, wherein the outlet end of the hollow fiber of the filter membrane is sealed and the inlet end is an open inlet.
In a fifth aspect according to the previous aspects, the filter membrane has a wall thickness in the range of approximately 150 μm to approximately 500 μm.
In a sixth aspect according to the previous aspects, the filter membrane has a longitudinal dimension in the range of approximately 3 cm to approximately 20 cm, an inner diameter in the range of approximately 2 mm to approximately 4 mm, and an outer diameter in the range of approximately 2.3 mm to approximately 5 mm.
In a seventh aspect according to the previous aspects, the filter membrane is made of at least one of the following materials: a polyolefin, polyvinylidene fluoride, polymethylmethacrylate, polyacrylonitrile, polysulfone, polyethersulfone, and a polymer containing cationic charges.
In an eighth aspect according to the previous aspects, the stem is one of a flexible stem or a rigid stem.
In a ninth aspect according to the previous aspects, the stem is made of at least one of the following materials: PVC, PET, a poly(meth)acrylate, a polycarbonate, a polyolefin, a cycloolefin copolymer, polystyrene, or a silicone polymer.
In a tenth aspect according to the previous aspects, the filter includes at least one U-shaped hollow fiber filter membrane secured in a U-shaped configuration by a filter membrane housing contained within a filter body.
In an eleventh aspect according to the previous aspects, the filter includes a plurality of U-shaped hollow fiber filter membranes.
In a twelfth aspect according to the previous aspects, the filter comprises a plurality of parallel hollow fiber membrane filters secured in a side-by-side configuration.
In a thirteenth aspect according to the previous aspects, the filter comprises a plurality of parallel hollow fiber membrane filters arranged in a circular pattern.
In a fourteenth aspect according to the previous aspects, the filter membrane has a nominal pore size in a range of approximately 0.1 μm to approximately 0.22 μm.
In a fifteenth aspect according to the previous aspects, the sterile solution product bag includes a plurality of bladders fluidly connected to one another directly, the stem and the filter being connected to the plurality of bladders for filling the product bag, wherein each bladder is connected to at least one other bladder at an edge between the bladders and each edge has an opening that puts the bladders in fluid communication, and wherein the single filter is connected to one of the bladders by an inlet.
In a sixteenth aspect according to the previous aspects, the sterile solution product bag includes a plurality of bladders fluidly connected to one another by a sealable tubing, the stem and the filter being connected to the plurality of bladders for filling the product bag, wherein the sealable tubing comprises a first part that extends to a juncture and a plurality of second parts extending from the junction to the plurality of bladders, each second part extending to one bladder.
According to an independent seventeenth aspect, a sterile solution product bag is provided which includes a bladder, a stem, and a filter. The stem has an inlet end and an outlet end, the outlet end of the stem fluidly connected to the bladder. The filter includes a porous filter membrane disposed within the stem, wherein the filter membrane is a hollow cylinder having a closed end disposed between the inlet and outlet ends of the stem and an open end disposed in proximity to the inlet end of the stem. The connector is connected to the inlet end of the stem and the open end of the filter, the connector having a solution inlet, a solution outlet, and a sealing surface disposed between the solution inlet and solution outlet, the solution outlet connected to the open end of the filter and the sealing surface connected to the inlet end of the stem, the solution inlet adapted to receive a solution for filtering through the stem and into the bladder.
In an eighteenth aspect according to the previous aspects, the porous filter membrane has a nominal pore size in a range of approximately 0.1 μm to approximately 0.5 μm.
In a nineteenth aspect according to the previous aspects, the filter membrane has a nominal pore size in a range of approximately 0.1 μm to approximately 0.22 μm.
In a twentieth aspect according to the previous aspects, the inlet end of the stem is fixed to the sealing surface of the connector, and the open end of the filter is fixed to the solution outlet of the connector.
In a twenty-first aspect according to the previous aspects, the solution outlet of the connector comprises a cylindrical member disposed inside of the open end of the filter.
In a twenty-second aspect according to the previous aspects, the filter comprises a plurality of filter membranes.
In a twenty-third aspect according to the previous aspects, the filter membrane has a wall thickness in the range of approximately 150 μm to approximately 500 μm.
In a twenty-fourth aspect according to the previous aspects, the filter membrane has a longitudinal dimension in the range of approximately 3 cm to approximately 20 cm, an inner diameter in the range of approximately 2 mm to approximately 4 mm, and an outer diameter in the range of approximately 2.3 mm to approximately 5 mm.
In a twenty-fifth aspect according to the previous aspects, the filter membrane is made of at least one of the following materials: a polyolefin, polyvinylidene fluoride, polymethylmethacrylate, polyacrylonitrile, polysulfone, polyethersulfone, and a polymer containing cationic charges.
In a twenty-sixth aspect according to the previous aspects, the stem is one of a flexible stem or a rigid stem.
In a twenty-seventh aspect according to the previous aspects, the stem is made of at least one of the following materials: PVC, PET, a poly(meth)acrylate, a polycarbonate, a polyolefin, a cycloolefin copolymer, polystyrene, or a silicone polymer.
In a twenty-eighth aspect according to the previous aspects, the sterile solution product bag is part of a continuous ambulatory peritoneal dialysis (CAPD) twin bag container system that further comprises a drain bag and a patient connector having a Y-junction connected to a first tubing connected to the product bag and a second tubing connected to the drain bag.
In a twenty-ninth aspect according to the previous aspects, an injection site is provided on the product bag.
In a thirtieth aspect according to the previous aspects, the first tubing connected to the product bag has a frangible portion.
In a thirty-first aspect according to the previous aspects, the patient connector has a sterility protector.
In a thirty-second aspect according to the previous aspects, the outlet of the stem connects to a Y-junction disposed along the first tubing connected to the product bag.
While the specification concludes with claims particularly pointing out and distinctly claiming the subject matter that is regarded as the present disclosure, it is believed that the disclosure will be more fully understood from the following description taken in conjunction with the accompanying drawings. Some of the figures may have been simplified by the omission of selected elements for the purpose of more clearly showing other elements. Such omissions of elements in some figures are not necessarily indicative of the presence or absence of particular elements in any of the exemplary embodiments, except as may be explicitly delineated in the corresponding written description. None of the drawings are necessarily to scale.
Referring to the figures in detail,
The stem 104 is a hollow narrow tube having an inlet 124 fluidly connected to the opening 114 of the bladder 102. The stem 104 includes a tapered head 126 defining the inlet 124, a collar 128 connecting a first stem part 130 to the tapered head 126, a second part 132, and a duct 134 defining a stem outlet 136. The sterile closure cap 108 has a hemispherical shaped knob 138 attached to a neck 140 that sealably covers the inlet 124 of the stem 104. The tapered head 126 may be a female fitting adapted for sealingly engaging a Luer fitting of a fluid supply line during filling, for example. The filter 106 having a flat sheet membrane 142 is disposed in-line with the stem 104 between the first and second parts 130, 132 of the stem 104. Non-limiting examples of acceptable filter membranes for the filter membrane 142 are disclosed in U.S. Patent Publication No. 2012/0074064 A1 and PCT Publication No. PCT/EP2015/068004, the entire contents of which are incorporated herein by reference.
So configured, a solution may enter the inlet 124 of the stem 104 and pass through the head 126 and into the first part 130 toward an inlet 144 of the filter 106. The solution then filters through the filter membrane 142, out a filter outlet 146, and into the second part 132 of the stem 104. The duct 134 carries the filtered solution from the second part 132 to the opening 114 of the bladder 102. The second part 132 of the stem 104 defined as the area of the stem between the outlet of the filter 146 and an inlet 148 of the duct 134 may be identified as a “seal and cut area”. The phrase “seal and cut area” pertains to the manner in which the product bags are sealed and cut after being filled. That is, the disclosed arrangement is designed such that after the bladder 102 is filled, a sealing mechanism can be employed to seal the stem 104 closed in the “seal and cut area,” which is below the filter membrane 142 but above the bladder 102. Thus, the “seal and cut area” 132 in this version is a portion of the stem 104 above the bladder 102 where the filter 106 does not reside. Sealing of the “seal and cut area” 132 can be achieved with a heat sealer or any other device, including for example clamping a clamp onto the “seal and cut area” 132. Once the stem 104 is sealed, the stem 104 is cut at a location above the seal but below the filter membrane 142. Cutting may be achieved with a knife or any other device. The stem 104 provides an isolated fluid connection between the inlet 124 and the bladder 102, such that once the solution is filtered through the filter membrane 142, the filtered solution passes directly into the sterilized environment of the bladder 102. Hence, after the bladder 102 is filled and the stem 104 is sealed and cut, the solution in the bladder 102 remains sterile until the bladder 102 is punctured or compromised. This, of course, assumes that the filter 106 was uncompromised prior to filling and performed as desired.
To ensure that the filter 106 performed properly, a filter integrity test can be performed on the filter 106. A filter integrity test is facilitated by the arrangement of the “seal and cut area” (second part 132) of the stem 104, which allows for the filter membrane 142 to be separated intact from the remainder of the now-sealed product bag 100. For example, after the stem 104 and filter 106 are separated from the product bag 100, a filter testing device (not shown) may be pre-programmed or controlled to perform a filter integrity test on the filter 106. Examples of filter integrity tests might include a bubble test, a pressure degradation test, a water intrusion test, a water flow test, or any suitable test known in the art. A pressure degradation test is a method for testing the quality of a filter either before or after the filter has been used. In the preferred embodiment, the filter 106 is tested after the solution passes through the filter membrane 142 and into the bladder 102 of the product bag 100. To perform the filter integrity test using a pressure degradation test procedure, a test head (not shown) engages the stem 104 and applies an air pressure of a predetermined value to the inlet 124 and filter membrane 142. In one embodiment, the pre-determined value is the pressure where gas cannot permeate the filter membrane 142 of an acceptable filter 106. A pressure sensor, or other method of measuring the integrity of the filter, is located within the test head and measures the pressure decay or diffusion rate through the filter membrane 142. The results from the integrity test are assessed to determine the quality of the filter 106, and therefore the quality of the solution that previously passed through the filter 106 and into the product bag 100. If the pressure sensor measures a decay or a unexpected rate of decay, then the filter 106 fails the test and it can be determined that the solution in the product bag is unsatisfactory. Alternatively in a bubble point test, the test head gradually increases the pressure applied to the filter 106, and the increase in pressure is measured in parallel with the diffusion rate of the gas through the filter membrane 142. Any disproportionate increase in diffusion rate in relation to the applied pressure may indicate a hole or other structural flaw in the filter membrane 142, and the filter would fail the integrity test.
Thus, it can be appreciated that the disclosed arrangement of the “seal and cut area” 132 of the product bag 100 disclosed herein advantageously facilitates the filter integrity test, and a determination that the solution of the filled product bag is either sterile or has the potential of being compromised may be made with a high degree of certainty.
An alternative product bag 150 illustrated in
As depicted in
The hollow connector 166 further includes a solution inlet 169. A pharmaceutical solution can be fed via a connected fluid supply line, for example, into the solution inlet 169 of the hollow connector 166. In some versions, the solution inlet 169 can include a Luer type fitting or other standard medical fitting. The pharmaceutical solution can then travel through the hollow connector 166 and exit into the filter 155 through the open outlet end 168 of the hollow connector 166. The hollow connector 166 also includes a sealing surface 172 to which the stem 156 is attached. The sealing surface 172 in this version is cylindrical and has a diameter larger than a diameter of the open outlet end 168, and is disposed generally concentric with the open outlet end 168. In fact, in this version, the outer diameter of the sealing surface 172 is generally identical to or slightly smaller than an inner diameter of the stem 156. So configured, the stem 156 receives the sealing surface 172 and extends therefrom to surround and protect the filter 155 without contacting the surface 164 of the filter 155. The stem 156 can be fixed to the sealing surface 172 with adhesive (e.g., a UV curing acrylic adhesive), epoxy, welding, bonding, etc. The stem 156 receives the pharmaceutical solution after it passes through the pores 162 in the filter 155. From there, the now filtered solution passes into the bladder 152.
The hollow connector 766 further includes a solution inlet 769, which is also a stem structure, extending in a second direction (opposite the first direction) from the bearing plate 777. A pharmaceutical solution can be fed via a connected fluid supply line, for example, into the solution inlet 769 of the hollow connector 766. In some versions, the solution inlet 769 can include a Luer type fitting or other standard medical fitting. The pharmaceutical solution can then travel through the hollow connector 766 and exit into the filter 155 through the open outlet end 768 of the hollow connector 766.
The hollow connector 766 also includes a sealing surface 772 to which the stem 156 is attached. The sealing surface 772 in this version is a cylindrical shroud extending from the bearing plate 777 in the first direction and has a diameter larger than a diameter of the open outlet end 768. The sealing surface 772 is disposed generally concentric with the open outlet end 768. As such, in this embodiment, the shroud of the sealing surface 772 surrounds the stem structure of the open outlet end 768 such that an annular gap 779 resides between the two. In fact, in this version, the outer diameter of the sealing surface 772 is generally identical to or slightly smaller than an inner diameter of the stem 156. So configured, the sealing surface 772 of the connector 766 can be received by the stem 156 such that the stem 156 extends therefrom to surround and protect the filter 155 without contacting the surface 164 of the filter 155. The stem 156 can be fixed to the sealing surface 772 with adhesive (e.g., a UV curing acrylic adhesive), epoxy, welding, bonding, etc. The stem 156 receives the pharmaceutical solution after it passes through the pores 162 in the filter 155. From there, the now filtered solution passes into the bladder 152 in the same manner described above with respect to
While the foregoing version of the filter 155 has been described as including a single filter membrane 170, in other embodiments within the scope of the present disclosure, the filter 155 may include multiple filter membranes 170. A few non-limiting examples of multiple membrane filters will be discussed below. Finally, as described with respect to the product bags 100, 150 in
In one version of the foregoing assembly of
Suitable materials for the filter membrane 170 can include polyolefins (e.g., PE, PP), polyvinylidene fluoride, polymethylmethacrylate, polyacrylonitrile, polysulfone, and polyethersulfone. In some embodiments within the scope of the present disclosure, the filter 155 may be comprised of a blend of polysulfone or polyethersulfone and polyvinylpyrrolidone. In other embodiments within the scope of the present disclosure, the filter membrane 170 can include a polymer containing cationic charges, e.g. polymers bearing functional groups like quaternary ammonium groups. A suitable example for such polymers is polyethyleneimine. The filter membrane 170 may be manufactured by known techniques including, e.g., extrusion, phase inversion, spinning, chemical vapor deposition, 3D printing, etc. Suitable materials for the stem 156 include PVC, polyesters like PET, poly(meth)acrylates like PMMA, polycarbonates (PC), polyolefins like PE, PP, or cycloolefin copolymers (COC), polystyrene (PS), silicone polymers, etc.
Additional details regarding some possible versions of the filter and the specific construction of the membrane, for example, can be found in European Patent Application No. EP16152332.9, entitled FILTER MEMBRANE AND DEVICE, filed Jan. 22, 2016, and additionally in PCT/EP2017/051044, entitled FILTER MEMBRANE AND DEVICE, filed Jan. 19, 2017, the entire contents of each of which are expressly incorporated herein by reference.
Thus far, the hollow fiber membrane 170 in
For example,
The hollow connector 866 also includes a sealing surface 872 to which the stem 156 is attached. The sealing surface 872 in this version is a cylindrical shroud extending from the bearing plate 877 in a direction opposite to a direction of extension of the solution inlet 869. The sealing surface 872 is disposed generally concentric with the solution inlet 869. As such, in this embodiment, the shroud of the sealing surface 872 defines a cylindrical cavity (not shown in the drawings) for receiving a portion of the second hollow body 866b of the connector 866.
The second hollow body 866b, as depicted, includes a support plate 880 and three open outlet ends 868 extending from the support plate 880. Additionally, the support plate 880 includes an outer diameter that is essentially the same as or slightly smaller than an inner diameter of the cavity of the shroud of the sealing surface 872 such that when assembled, the support plate 880 is positioned into the cavity. In one version, the support plate 880 includes a seal member 882 around its periphery to form a fluid tight seal with the inner surface of the shroud of the sealing surface 872 when inserted into the cavity. Friction, adhesive, or some other means may retain the support plate 880 in connection with the shroud of the sealing surface 872.
As mentioned, the second body 866b includes three open outlet ends 868 extending from the support plate 880. Each open outlet end 868 is adapted to be sealingly connected to an open inlet end 160 of one of three filters 155. The connection may be achieved by gluing open inlet ends 160 of the filters 155 to the open outlet ends 868 with, for example, an epoxy resin, a polyurethane resin, a cyanoacrylate resin, a UV curing acrylic adhesive, or a solvent for the material of the hollow connector 766 such as cyclohexanone. In the version depicted, the stem structure of the open outlet ends 868 of the connector 866 comprises a hollow cylindrical member that fits inside of and is fixed to the open inlet ends 160 of the filters 155. As such, an outer diameter of the open outlet ends 868 is substantially similar to or slightly smaller than an inner diameter of the open inlet ends 160 of the filters 155. In some versions, the filters 155 may be welded to the open outlet ends 868 of the connector 866 by, for example, heat welding (e.g., introducing a hot conical metal tip into the open inlet ends 150 of the filters 155 to partially melt it), laser welding if the hollow connector 866 is made from a material that absorbs laser radiation, mirror welding, ultrasound welding, and friction welding. Alternately, the filters 155 may be inserted into a mold, and a thermoplastic polymer may be injection-molded around it to form the hollow connector 866. Other designs and configurations for connecting the filters 155 to the open outlet ends 868 are intended to be within the scope of the present disclosure.
Finally, as with previously described embodiments, the sealing surface 872 of the connector 866 can be received by the stem 156 such that the stem 156 extends therefrom to surround and protect the filters 155 without contacting the surfaces 164 of the filters 155. The stem 156 can be fixed to the sealing surface 872 with adhesive (e.g., a UV curing acrylic adhesive), epoxy, welding, bonding, etc. The stem 156 receives the pharmaceutical solution after it passes through the pores 162 in the filter 155. From there, the now filtered solution passes into the bladder 152 in the same manner described above with respect to
The second hollow body 866b, as depicted, includes a hollow cylindrical support collar 980 in which seven hollow fiber membrane filters 955 can be disposed parallel to each other, as shown in
Finally, the collar 980 of this embodiment includes a sealing surface 972 that can be received by the stem 156 such that the stem 156 extends therefrom. The stem 156 can be fixed to the sealing surface 972 with adhesive (e.g., a UV curing acrylic adhesive), epoxy, welding, bonding, etc. The stem 156 receives the pharmaceutical solution after it passes through the pores 162 in the filters 955. From there, the now filtered solution passes into the bladder 152 in the same manner described above with respect to
In some embodiments within the scope of the present disclosure, more than one product bag may be filled by a single filter.
The filter assembly 1018 depicted in
While certain representative versions of the claimed subject matter have been described herein for purposes of illustrating the invention, it will be apparent to those skilled in the art that various changes in the devices and methods disclosed may be made without departing from the spirit and scope of the invention, which is defined by the following claims and is not limited in any manner by the foregoing description.
This is a Continuation of U.S. patent application Ser. No. 16/070,009, filed Jul. 13, 2018, which is the United States National Phase of International Patent Application No. PCT/US2017/014253, filed Jan. 20, 2017, which claims the priority benefit of U.S. Provisional Patent Application No. 62/281,799, filed Jan. 22, 2016. The entire contents of each of the foregoing are hereby incorporated herein by reference.
Number | Name | Date | Kind |
---|---|---|---|
3233384 | Barton et al. | Feb 1966 | A |
3902068 | Wood | Aug 1975 | A |
3938519 | McPhee | Feb 1976 | A |
4036698 | Bush et al. | Jul 1977 | A |
4116646 | Edwards | Sep 1978 | A |
4265760 | Abel et al. | May 1981 | A |
4353398 | Weiler et al. | Oct 1982 | A |
4360435 | Bellamy et al. | Nov 1982 | A |
4369898 | Andersson | Jan 1983 | A |
4502614 | Weiler et al. | Mar 1985 | A |
4507114 | Bohman et al. | Mar 1985 | A |
4515007 | Herman | May 1985 | A |
4521366 | Mason et al. | Jun 1985 | A |
4547289 | Okano et al. | Oct 1985 | A |
4610790 | Reti et al. | Sep 1986 | A |
4623516 | Weiler et al. | Nov 1986 | A |
4636307 | Inoue et al. | Jan 1987 | A |
4636313 | Vaillancourt | Jan 1987 | A |
4668401 | Okumura et al. | May 1987 | A |
4671762 | Weiler et al. | Jun 1987 | A |
4695382 | Cronin | Sep 1987 | A |
4712590 | Gianfilippo | Dec 1987 | A |
4730435 | Riddle et al. | Mar 1988 | A |
4738782 | Yamauchi et al. | Apr 1988 | A |
4779448 | Gogins | Oct 1988 | A |
4807676 | Cerny et al. | Feb 1989 | A |
4820297 | Kaufman et al. | Apr 1989 | A |
4842028 | Kaufman et al. | Jun 1989 | A |
4872974 | Hirayama et al. | Oct 1989 | A |
4881176 | Kononov | Nov 1989 | A |
4915847 | Dillon et al. | Apr 1990 | A |
4937194 | Pattillo et al. | Jun 1990 | A |
4943287 | Carmen | Jul 1990 | A |
4997430 | Van der Heiden et al. | Mar 1991 | A |
5064529 | Hirayama et al. | Nov 1991 | A |
RE33924 | Valeri | May 1992 | E |
5180504 | Johnson et al. | Jan 1993 | A |
5209044 | D'Addario et al. | May 1993 | A |
5221474 | Yokono et al. | Jun 1993 | A |
5249409 | Jensen | Oct 1993 | A |
5275724 | Bucchianeri et al. | Jan 1994 | A |
5310094 | Martinez et al. | May 1994 | A |
5353630 | Soda et al. | Oct 1994 | A |
5368586 | Van Der Heiden et al. | Nov 1994 | A |
5417101 | Weich | May 1995 | A |
5476592 | Simard | Dec 1995 | A |
5480554 | Degen et al. | Jan 1996 | A |
5488811 | Wang et al. | Feb 1996 | A |
5490848 | Finley et al. | Feb 1996 | A |
5493845 | Adolf et al. | Feb 1996 | A |
5507959 | Glick | Apr 1996 | A |
5538638 | Hedman | Jul 1996 | A |
5563334 | Bracht et al. | Oct 1996 | A |
5584997 | Yagihashi et al. | Dec 1996 | A |
5594161 | Randhahn et al. | Jan 1997 | A |
5616828 | Kuczenski | Apr 1997 | A |
5674404 | Kenley et al. | Oct 1997 | A |
5733619 | Patel et al. | Mar 1998 | A |
5788862 | Degen et al. | Aug 1998 | A |
5808181 | Wamsiedler et al. | Sep 1998 | A |
5881535 | Gliniecki et al. | Mar 1999 | A |
5911886 | Delmas | Jun 1999 | A |
6059968 | Wolf, Jr. | May 2000 | A |
6149997 | Patel et al. | Nov 2000 | A |
6228271 | Cote | May 2001 | B1 |
6245228 | Kelada | Jun 2001 | B1 |
6324898 | Cote et al. | Dec 2001 | B1 |
6358420 | Blickhan et al. | Mar 2002 | B2 |
6451201 | Cadera et al. | Sep 2002 | B1 |
6465068 | Patel et al. | Oct 2002 | B1 |
6495039 | Lee et al. | Dec 2002 | B1 |
6504606 | Yagita | Jan 2003 | B2 |
6660171 | Zuk, Jr. | Dec 2003 | B2 |
6666970 | Jornitz et al. | Dec 2003 | B1 |
6904370 | Levinson et al. | Jun 2005 | B1 |
6983504 | Grummert et al. | Jan 2006 | B2 |
7048775 | Jornitz et al. | May 2006 | B2 |
7117901 | Martinell Gisper-Sauch et al. | Oct 2006 | B2 |
7166217 | Holmes et al. | Jan 2007 | B2 |
7281409 | Baumfalk et al. | Oct 2007 | B2 |
7354758 | Guenec et al. | Apr 2008 | B2 |
7396451 | Holmes et al. | Jul 2008 | B2 |
7413665 | Holmes et al. | Aug 2008 | B2 |
7444795 | Yasuhira | Nov 2008 | B2 |
7544300 | Brugger et al. | Jun 2009 | B2 |
7592178 | Ding et al. | Sep 2009 | B2 |
7594425 | Lewnard et al. | Sep 2009 | B2 |
7727219 | Lampeter | Jun 2010 | B2 |
7749393 | Brugger et al. | Jul 2010 | B2 |
7770434 | Brussermann et al. | Aug 2010 | B2 |
7972515 | Mangum et al. | Jul 2011 | B1 |
8003768 | Gordon | Aug 2011 | B1 |
8225824 | Eliuk et al. | Jul 2012 | B2 |
8267912 | Ferris | Sep 2012 | B2 |
8271139 | Bellafiore et al. | Sep 2012 | B2 |
8272251 | Jons et al. | Sep 2012 | B2 |
8361320 | Zuk, Jr. | Jan 2013 | B2 |
8366855 | Murray | Feb 2013 | B2 |
8499919 | Giribona et al. | Aug 2013 | B2 |
8865064 | Meier et al. | Oct 2014 | B2 |
9072996 | Jornitz et al. | Jul 2015 | B2 |
9095801 | Stering | Aug 2015 | B2 |
20020117232 | Gisper-Sauch et al. | Aug 2002 | A1 |
20020162778 | Peabody et al. | Nov 2002 | A1 |
20030174306 | Grant et al. | Sep 2003 | A1 |
20030230521 | Schick | Dec 2003 | A1 |
20030234211 | Seiler et al. | Dec 2003 | A1 |
20040007540 | Verpoort et al. | Jan 2004 | A1 |
20040022696 | Zigler et al. | Feb 2004 | A1 |
20040031744 | Nakashima | Feb 2004 | A1 |
20040147865 | Cianci et al. | Jul 2004 | A1 |
20040155066 | Schick | Aug 2004 | A1 |
20040226898 | Halstead et al. | Nov 2004 | A1 |
20040237654 | Savaii et al. | Dec 2004 | A1 |
20050209547 | Burbank et al. | Sep 2005 | A1 |
20050279419 | Tribble et al. | Dec 2005 | A1 |
20060048486 | Laing et al. | Mar 2006 | A1 |
20060054557 | Hori | Mar 2006 | A1 |
20060124515 | Rajagopalan et al. | Jun 2006 | A1 |
20070079649 | Nauseda et al. | Apr 2007 | A1 |
20070119121 | Woods et al. | May 2007 | A1 |
20070175816 | Verpoort et al. | Aug 2007 | A1 |
20070251299 | Brussermann et al. | Nov 2007 | A1 |
20080051937 | Khan et al. | Feb 2008 | A1 |
20080087613 | Hudock et al. | Apr 2008 | A1 |
20080105618 | Beckius et al. | May 2008 | A1 |
20090173685 | Imai et al. | Jul 2009 | A1 |
20090299651 | Sadar | Dec 2009 | A1 |
20100004588 | Yeh et al. | Jan 2010 | A1 |
20100004602 | Nord et al. | Jan 2010 | A1 |
20100004619 | Rondeau et al. | Jan 2010 | A1 |
20110049026 | Ryu et al. | Mar 2011 | A1 |
20110067485 | Grant et al. | Mar 2011 | A1 |
20110094310 | DiLeo et al. | Apr 2011 | A1 |
20110094619 | Steel et al. | Apr 2011 | A1 |
20120024156 | Yoshida et al. | Feb 2012 | A1 |
20120080375 | Scheu et al. | Apr 2012 | A1 |
20120222774 | Husnu et al. | Sep 2012 | A1 |
20120282143 | Marquis et al. | Nov 2012 | A1 |
20120297862 | Mayr et al. | Nov 2012 | A1 |
20130055794 | Armour | Mar 2013 | A1 |
20130130973 | Wahren et al. | May 2013 | A1 |
20130233810 | Zuk, Jr. | Sep 2013 | A1 |
20130240436 | Johnson et al. | Sep 2013 | A1 |
20140012185 | Ishizuka | Jan 2014 | A1 |
20140033798 | Peeler et al. | Feb 2014 | A1 |
20140083170 | Pavlik | Mar 2014 | A1 |
20140238110 | Williams | Aug 2014 | A1 |
20150033828 | Li et al. | Feb 2015 | A1 |
20150265958 | Brown et al. | Sep 2015 | A1 |
20150283479 | Perreault et al. | Oct 2015 | A1 |
20150284173 | Defemme et al. | Oct 2015 | A1 |
20150298995 | Johann et al. | Oct 2015 | A1 |
20150307606 | Basarkar et al. | Oct 2015 | A1 |
20160201019 | Stokes et al. | Jul 2016 | A1 |
Number | Date | Country |
---|---|---|
2498602 | Jul 2002 | CN |
101816846 | Sep 2010 | CN |
201643862 | Nov 2010 | CN |
201732014 | Feb 2011 | CN |
102109364 | Jun 2011 | CN |
201939752 | Aug 2011 | CN |
102313691 | Jan 2012 | CN |
102430340 | May 2012 | CN |
102435224 | May 2012 | CN |
102947186 | Feb 2013 | CN |
103393542 | Nov 2013 | CN |
103476381 | Dec 2013 | CN |
203337507 | Dec 2013 | CN |
203493987 | Mar 2014 | CN |
104048839 | Sep 2014 | CN |
204797991 | Nov 2015 | CN |
105209342 | Dec 2015 | CN |
204910247 | Dec 2015 | CN |
204988705 | Jan 2016 | CN |
205262990 | May 2016 | CN |
15004569 | Jul 2015 | CO |
3238649 | Apr 1984 | DE |
3333283 | Apr 1985 | DE |
4339589 | Dec 1994 | DE |
29618092 | Dec 1996 | DE |
20212749 | Oct 2002 | DE |
10151270 | May 2003 | DE |
202010017082 | May 2011 | DE |
10165044 | Jan 2013 | DE |
102011111050 | Feb 2013 | DE |
102012216772 | Mar 2014 | DE |
202015101765 | Apr 2015 | DE |
102014113638 | Mar 2016 | DE |
0116362 | Aug 1984 | EP |
0314822 | May 1989 | EP |
0476194 | Mar 1992 | EP |
0582822 | Feb 1994 | EP |
0667954 | Aug 1995 | EP |
0624359 | May 1997 | EP |
0790051 | Aug 1997 | EP |
0545000 | Oct 1997 | EP |
0820343 | Jan 1998 | EP |
1579838 | Sep 2005 | EP |
1775002 | Apr 2007 | EP |
1882486 | Jan 2008 | EP |
1935470 | Jun 2008 | EP |
2012906 | Jan 2009 | EP |
2059443 | May 2009 | EP |
2260918 | Dec 2010 | EP |
2331078 | Jun 2011 | EP |
2502610 | Sep 2012 | EP |
2658502 | Nov 2013 | EP |
2684551 | Jan 2014 | EP |
2767583 | Aug 2014 | EP |
2840379 | Feb 2015 | EP |
2909904 | Jun 2008 | FR |
2153247 | Aug 1985 | GB |
2362841 | Dec 2001 | GB |
2365511 | Feb 2002 | GB |
VR980047 | Nov 1999 | IT |
S5840202 | Mar 1983 | JP |
S6058530 | Apr 1985 | JP |
6091203 | Jun 1985 | JP |
S60197287 | Oct 1985 | JP |
S621410 | Jan 1987 | JP |
H01139108 | May 1989 | JP |
02290228 | Nov 1990 | JP |
H038420 | Jan 1991 | JP |
H03110445 | May 1991 | JP |
H04142445 | May 1992 | JP |
H04348252 | Dec 1992 | JP |
H0523551 | Feb 1993 | JP |
H0643089 | Feb 1994 | JP |
6-34636 | May 1994 | JP |
H10225628 | Aug 1998 | JP |
2009-519440 | May 2009 | JP |
5389885 | Jan 2014 | JP |
2014128780 | Jul 2014 | JP |
2014521405 | Aug 2014 | JP |
2015-74457 | Apr 2015 | JP |
2389513 | May 2010 | RU |
247843 | Jul 1969 | SU |
WO-8803829 | Jun 1988 | WO |
WO-9614913 | May 1996 | WO |
WO-2004009201 | Jan 2004 | WO |
WO-2004096319 | Nov 2004 | WO |
WO-2005077499 | Aug 2005 | WO |
WO-2008039278 | Apr 2008 | WO |
WO-2009006850 | Jan 2009 | WO |
WO-2010065810 | Jun 2010 | WO |
WO-2011154072 | Dec 2011 | WO |
WO-2012103124 | Aug 2012 | WO |
WO-2013009765 | Jan 2013 | WO |
WO-2013186631 | Dec 2013 | WO |
WO-2014008400 | Jan 2014 | WO |
WO-2014105946 | Jul 2014 | WO |
WO-2014147159 | Sep 2014 | WO |
WO-2015023468 | Feb 2015 | WO |
WO-2015082855 | Jun 2015 | WO |
WO-2016030013 | Mar 2016 | WO |
WO-2016109230 | Jul 2016 | WO |
Entry |
---|
European Patent Application No. 19203850.3, Search Report, dated Jan. 14, 2020. |
Russian Patent Application No. 2018127841, Office Action, dated Dec. 6, 2019. |
European Patent Application No. 19203850.3, Communication Pursuant to Article 94(3) EPC, dated Oct. 25, 2021. |
Indian Patent Application No. 201817022502, First Examination Report, dated Apr. 27, 2020. |
Chinese Patent Application No. 201780007376.7, Office Action, dated Jul. 15, 2020. |
Japanese Patent Application No. 2019-173870, Notice of Reasons for Rejection, dated Feb. 5, 2021. |
International Search Report and Written Opinion of the International Application No. PCT/US2017/014253, dated Apr. 26, 2017. |
Israel Patent Application No. 260097, Notification of Defects, dated Nov. 5, 2018. |
Japanese Patent Application No. 2018-536427, Notice of Reasons for Rejection, dated Feb. 5, 2019. |
Russian Patent Application No. 2018127841, Official Action and Search Report, dated Feb. 14, 2019. |
Australian Patent Application No. 2018253530, Examination Report No. 1, dated Mar. 11, 2019. |
German Patent Application No. 11 2017 000 470.5, Office Action, dated May 27, 2019. |
Japanese Patent Application No. 2018-536427, Final Office Action, dated Jun. 13, 2019. |
Russian Patent Application No. 2018127841, Office Action, dated Jul. 8, 2019. |
U.S. Appl. No. 16/070,009, Nonfinal Office Action, dated Sep. 19, 2019. |
Philippines Patent Application No. 1-2018-501561, Substantive Examination Report, dated Nov. 7, 2019. |
European Patent Application No. 19203850.3, Communication Pursuant to Article 94(3) EPC, dated Feb. 17, 2021. |
Brazil Patent Application No. BR112018013901-7, Office Action, dated Aug. 9, 2022. |
Number | Date | Country | |
---|---|---|---|
20200113781 A1 | Apr 2020 | US |
Number | Date | Country | |
---|---|---|---|
62281799 | Jan 2016 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 16070009 | US | |
Child | 16711338 | US |